In8bio Inc (INAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, In8bio Inc (INAB) has a cash flow conversion efficiency ratio of -0.217x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.95 Million) by net assets ($22.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can In8bio Inc fund operations to measure how many days the company can operate on defensive assets alone.
In8bio Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how In8bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
In8bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of In8bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KOAS Co. Ltd
KO:071950
|
0.001x |
|
Maha Rashtra Apex Corporation Limited
NSE:MAHAPEXLTD
|
-0.003x |
|
MRO-TEK Realty Limited
NSE:MRO-TEK
|
0.014x |
|
Careplus Group Bhd
KLSE:0163
|
-0.058x |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
-0.507x |
|
Minox International Group Berhad
KLSE:0288
|
0.026x |
|
Senior PLC
LSE:SNR
|
0.147x |
|
Sampann Utpadan India Limited
NSE:SAMPANN
|
-0.203x |
Annual Cash Flow Conversion Efficiency for In8bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of In8bio Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see In8bio Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.56 Million | $-12.71 Million | -0.461x | +72.34% |
| 2024-12-31 | $14.48 Million | $-24.15 Million | -1.668x | -78.21% |
| 2023-12-31 | $24.94 Million | $-23.34 Million | -0.936x | +11.79% |
| 2022-12-31 | $22.73 Million | $-24.12 Million | -1.061x | -199.92% |
| 2021-12-31 | $38.18 Million | $-13.51 Million | -0.354x | +9.13% |
| 2020-12-31 | $18.32 Million | $-7.13 Million | -0.389x | -102.81% |
| 2019-12-31 | $-346.00K | $-4.80 Million | 13.876x | +2428.66% |
| 2018-12-31 | $4.65 Million | $-2.77 Million | -0.596x | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more